Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Drug Risk Communication Should Include Drug Benefit Info, PhRMA Says

Executive Summary

FDA risk communication materials should include information about a drug's benefits to avoid scaring patients away from their medications, the Pharmaceutical Research & Manufacturers of America said

You may also be interested in...



FDA Poised To Overhaul Distribution Of Consumer Medical Information

FDA appears poised to begin an overhaul of the dissemination of consumer drug information

FDA Poised To Overhaul Distribution Of Consumer Medical Information

FDA appears poised to begin an overhaul of the dissemination of consumer drug information

FDA’s Internal Research Activities Will Get Broad Review By Science Board

FDA's Science Board is conducting a strategic review of agency research projects as part of an effort to reduce duplication and identify deficient areas

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel